Insider trade

CEO sold ~$12.3M of ROIV shares in the open market

Traded Dec 15, 2025 · Filed Dec 18, 2025

Why it stands out

The boss of Roivant Sciences sold $12.3M of Roivant Sciences shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

CEO$1M+

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$12,273,395

Shares × reported transaction price

Timing vs results

35 days after results of Nov 10, 2025, 53 days before results of Feb 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−0.8%	+1.4%	−2.2%
30 days	+2.5%	−0.4%	+3.0%
90 days	+24.1%	−3.0%	+27.1%
180 days	+39.2%	+8.9%	+30.4%

Past results only. Not a forecast.

All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934.

9mo ago

Derivative exercise or conversion — not an open-market buy.

Automatic sale9mo ago

9mo ago

Derivative exercise or conversion — not an open-market buy.